Return to content in this issue


Dupilumab as an Effective Therapy for Corticosteroid-Dependent/Resistant Type 2 Inflammation-Related Cutaneous Adverse Reactions

Shen Ch1,2*, Wu N1,2*, Liu Yang L1,2, Wang B3, Liu T1,2, Tao J1,2

1Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
2Hubei Engineering Research Center of Skin Disease Theranostics and Health, Wuhan, China.
3Department of Dermatology, University of Michigan, Ann Arbor, Michigan, United States.
*These two authors contribute equally to this work.

J Investig Allergol Clin Immunol 2024; Vol. 34(2)
doi: 10.18176/jiaci.0944

Key words: Drug rash, Corticosteroid-resistant, Dupilumab, Th2 pathway, DRESS syndrome